Locoregional IL-2 low dose applications for gastrointestinal tumors  

作　　者：Zachary Krastev V Koltchakov R Tomova S Deredjian A Alexiev D Popov B Tomov Jan-Willem Koten John Jacobs Willem Den Otter 

机构地区：[1]Clinic of Gastroenterology Faculty of Medicine, University Hospital, Blvd. Iv.Geshov 15,Sofia 1431,Bulgaria [2]Department of Pathobiology PO Box 80.178, 3508 TD Utrecht, The Netherlands [3]Clinic of Gastroenterology Faculty of Medicine, Univeisity Hospital, Blvd. Iv.Geshov 15,Sofia 1431,Bulgaria

出　　处：《World Journal of Gastroenterology》2005年第35期5525-5529,共5页世界胃肠病学杂志（英文版）

摘　　要：AIM： To explore the feasibility of local interleukin 2 （IL-2） in patients with different forms of abdominal cancer. This required experimentation with the time interval between IL-2 applications and the methods of application. METHODS： Sixteen patients with stages Ⅲ and Ⅳ of gastrointestinal malignancies （primary or metastatic） who were admitted to our Department of Gastroenterology were treated with Iocoregionally applied IL-2 in low doses. RESULTS： No major problems applying Iocoregional IL-2 were encountered. In 6 out of 16 patients, a modest but clinically worthwhile improvement was obtained. Adverse effects were minimal. The therapeutic scheme was well tolerated, even in patients in a poor condition. CONCLUSION： This study demonstrates the feasibility of low dose Iocoregional IL-2 application in advanced abdominal cancer. Local IL-2 therapy gives only negligible adverse effects. The results suggest that it is important to apply intratumorally. Local IL-2 may be given adjunct to standard therapeutic regimes and does not imply complex surgical interventions. These initial results are encouraging.AIM: To explore the feasibility of local interleukin 2 (IL-2)in patients with different forms of abdominal cancer. This required experimentation with the time interval between IL-2 applications and the methods of application.METHODS: Sixteen patients with stages Ⅲ and Ⅳ of gastrointestinal malignancies (primary or metastatic) who were admitted to our Department of Gastroenterology were treated with locoregionally applied IL-2 in low doses.RESULTS: No major problems applying locoregional IL-2 were encountered. In 6 out of 16 patients, a modest but clinically worthwhile improvement was obtained. Adverse effects were minimal, The therapeutic scheme was well tolerated, even in patients in a poor condition.CONCLUSION: This study demonstrates the feasibility of low dose locoregional IL-2 application in advanced abdominal cancer. Local IL-2 therapy gives only negligible adverse effects. The results suggest that it is important to apply intratumorally. Local IL-2 may be given adjunct to standard therapeutic regimes and does not imply complex surgical interventions. These initial results are encouraging.

关 键 词：INTERLEUKIN-2 Local IL-2 therapy Gastrointestinalcancer 

分 类 号：R735[医药卫生—肿瘤]